Observational studyEuropean heart journal2023
Primary prevention of acute cardiovascular events by influenza vaccination: an observational study.
Observational study in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Systematic review and meta-analysis of respiratory viral triggers for acute myocardial infarction and stroke.Cardiovascular research · 2025Pooled it
- Quality indicators for the primary prevention of cardiovascular disease in primary care: A systematic review.PloS one · 2024Pooled it
- Evaluation of influenza vaccine effectiveness among older adults in Jiaxing, China, 2022-2025: A test negative design-based study.Human vaccines & immunotherapeutics · 2026Article
- 2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans.JAMA internal medicine · 2026Article
- Influenza Vaccination as Cardiovascular Prevention in Adults with Heart Disease.Journal of clinical medicine · 2026Review
- High-dose quadrivalent influenza vaccine in older adults with or without cardiovascular risk: a meta-analysis of randomized trials on 511,890 participants.Immunity & ageing : I & A · 2026Review
- Potential Non-Specific Benefits of Seasonal Influenza Vaccination: Evidence, Knowledge Gaps, and Future Directions.Vaccines · 2026Review
- Article
- Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal causal inference.EClinicalMedicine · 2025Article
- Article
- Is Influenza Vaccination Our Best 'Shot' at Preventing MACE? Review of Current Evidence, Underlying Mechanisms, and Future Directions.Vaccines · 2025Review
- Article
- Article
- [Vaccination and cardiovascular diseases].Herz · 2025Review
- Diagnosing and treating stable angina: a contemporary approach for practicing physicians.Future cardiology · 2025Review
- Neurologic Complications of Influenza and Potential Protective Vaccine Effects.Influenza and other respiratory viruses · 2025Review
- Respiratory Syncytial Virus-Associated Respiratory Diseases in Children and Adults.Deutsches Arzteblatt international · 2024Review
- ERS International Congress 2023: highlights from the Respiratory Infections Assembly.ERJ open research · 2024Article
- Specific and Nonspecific Effects of Influenza Vaccines.Vaccines · 2024Review
- Laboratory-confirmed respiratory viral infection triggers for acute myocardial infarction and stroke: Systematic review protocol.PloS one · 2024Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
aimsPrevious studies show a reduced incidence of first myocardial infarction and stroke 1-3 months after influenza vaccination, but it is unclear how underlying cardiovascular risk impacts the association. METHODS AND
resultsThe study used linked Clinical Practice Research Datalink, Hospital Episode Statistics Admitted Patient Care and Office for National Statistics mortality data from England between 1 September 2008 and 31 August 2019. From the data, individuals aged 40-84 years with a first acute cardiovascular event and influenza vaccination occurring within 12 months of each September were selected. Using a self-controlled case series analysis, season-adjusted cardiovascular risk stratified incidence ratios (IRs) for cardiovascular events after vaccination compared with baseline time before and >120 days after vaccination were generated. 193 900 individuals with a first acute cardiovascular event and influenza vaccine were included. 105 539 had hypertension and 172 050 had a QRISK2 score ≥10%. In main analysis, acute cardiovascular event risk was reduced in the 15-28 days after vaccination [IR 0.72 (95% CI 0.70-0.74)] and, while the effect size tapered, remained reduced to 91-120 days after vaccination [0.83 (0.81-0.88)]. Reduced cardiovascular events were seen after vaccination among individuals of all age groups and with raised and low cardiovascular risk.
conclusionsInfluenza vaccine may offer cardiovascular benefit among individuals at varying cardiovascular risk. Further studies are needed to characterize the populations who could derive the most cardiovascular benefits from vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.